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ABSTRACT 
________________________________________________________________ 
We report the novel synthesis of cyclic PLP139-151 (cPLP) and its application in SJL/J mice to 
study its encephalitogenic effects. Our results indicate that the cPLP analog is minimally 
encephalitogenic when administered to induce experimental autoimmune encephalomyelitis 
(low disease burden, minimal inflammatory, demyelinating and axonopathic pathology 
compared to its linear counterpart). Proliferation assays confirmed the low stimulatory potential 
of the cPLP compared to linPLP (2.5-fold lower proliferation) as well as inducing lower 
antibody responses. Molecular modeling showed a completely different TCR recognition 
profile of cPLP in regard to linPLP, where H147 replaces W144 and F151-K150 replace H147 as 
TCR contacts, which may explain the difference on each peptide’s response.  
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1. Introduction 
 
Experimental autoimmune encephalomyelitis (EAE) is an experimental model of 
demyelination, inflammatory processes and axonopathy within the central nervous system 
(CNS) of susceptible animals, using the triggering of various CNS antigens such as myelin 
basic protein (MBP), proteolipid protein (PLP) and myelin oligodendrocyte glycoprotein (MOG) 
or their peptides [1]. Due to the similarities of EAE with multiple sclerosis (MS), this model is 
widely used to study pathological mechanisms as well as novel experimental treatments for 
the disease [2-4]. Peptides PLP40-70, PLP100-119, PLP178-191 and PLP139-151 are the major 
encephalitogenic epitopes in the mouse strain SJL/J (I-As) [5-7]. Both of PLP178-191 and PLP139-
151 peptides bind with similar affinity to major histocompatibility (MHC) class II (MHC-II; I-As), 
although, PLP139-151 elicits stronger immune responses and EAE in SJL/J mice [6].  
 The peptides that induce EAE bear different immunogenic properties in each animal 
species which is largely determined by the specific properties of the major histocompatibility 
complex (MHC)-II haplotype of the animal. Specific peptide motifs within the antigen-binding 
groove of the MHC complex determines the affinity to the antigen and subsequent T-cell 
receptor (TCR) recognition and activation of the cell [8]. This MHC-antigen-TCR trimolecular 
complex is the key step to induce EAE with antigenic peptides and is possibly a key factor to 
MS immune-pathology [9, 10]. In fact, a number of immunotherapeutic strategies are based on 
blocking the formation of this complex, such as, anti-MHC-II antibodies or anti-CD4 antibodies 
which consequently suppress EAE [11-13]. In addition, any modification to the antigenic 
peptide, and any caused deviation from a tight MHC-antigen-TCR match can lead to reduced 
T-cell activation and different profiles of secreted cytokines. 
Based on this concept, there have been several attempts to alter the trimolecular 
complex affinities and render autoreactive T-cells in MS and EAE inactive or eliminated. This 
approach of altered peptide ligands (APL; 1-2 amino acid modifications within a peptide) have 
resulted in immunomodulation of immune responses from pro- to anti-inflammatory. In fact, we 
have shown that 1-2 amino acid mutations to MBP peptide induces anti-inflammatory 
cytokines, which can be further diverted from T helper (Th)-1 to Th2 when conjugated to a 
novel carrier mannan [14-22]. Likewise, substitution of the TCR binding amino acids at 
positions 144 (Tryptophan, W) and 147 (Histidine, H) to L144 and R147 was able to antagonise T 
cell clones specific for PLP139-151 epitope, block the induction of EAE and prevent progression 
of EAE [3, 16, 23, 24]. An alternative approach was recently published, whereby non-peptide 
mimetics of MBP83–96 T cell epitope can function as TCR antagonists by the inclusion of 
compounds obtained through the ZINC database [25]. Hence such an approach may pave the 
way to developing alternative and improved immunotherapeutics against MS [25]. 
 Using alternative approaches to altering the tight interaction of the trimolecular 
complex, we recently showed that cyclic MOG35-55 peptide had a significant lower immunogenic 
potential in appropriate recipient animals (C57BL/6 mice), due to reduced affinity to MHC-II 
alleles [26]. In the present study we studied the immunogenic properties of novel synthesized 
cyclic (head to tail) PLP139-151 peptide (cyclo(139-151)PLP139-151; cPLP), using our previous 
successfully established process [26]. By keeping the same antigenic linear epitope of PLP139-
151 (linPLP) that induces EAE in SJL/J mice and changing the sterotaxy of the molecule to a 
cyclic one (cPLP), we tested the in vivo immunogenic and encephalitogenic potential of the 
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specific cPLP and linPLP peptides in SJL/J mice. Additionally, we determined the interactions 
of the cPLP peptide compared to linPLP counterpart in complex with MHC-II (H-2 IAs) using 
appropriate in silico binding and structural studies (docking and homology modelling).  
 
2. Results and discussion 
 
 Immunotherapeutic strategies have involved APL of peptide constituents of the myelin 
sheath (MBP, PLP and MOG) that are able to modulate/divert immune responses from pro-
inflammatory (Th1) to anti-inflammatory (Th2) [18]. We recently demonstrated for the first time 
in a different mouse model (C57BL/6) that cMOG35-55 peptide was able to significantly 
ameliorate clinical disease and underlying pathology when co-administered with 
encephalitogenic linear MOG35-55 peptide, in both acute and chronic phases of EAE [26]. 
Herein, we showed, in the SJL/J mouse model that cyclization (cPLP) of the encephalitogenic 
linPLP peptide alters histopathological outcomes and disease severity of EAE in mice. Such 
cyclic modifications of linear peptides may provide novel immunomodulatory approaches for 
the future against MS [27]. 
 
2.1. Cyclic PLP is only minimal encephalitogenic compared to its linear analog  
 
 Animals of the control group developed a single-relapse EAE with a residual clinical 
disease after the remission. No second relapse was observed during the period of 
experimental clinical observation (Fig. 1A). The group of linPLP (control) developed severe 
EAE disease with overall disease burden (AUC of 75.9±44.4), maximal disease deficits (MMS 
of 4.4±1.4) and dDO at 8.1±1.7 days (Fig. 1B-D). Importantly, 3/9 control mice died within the 
acute phase of EAE (up to day 16) and 89 % (8/9) of the mice reached or exceeded score 3 
(Fig. 1E), all signs of a highly severe EAE. However, mice immunized with the cPLP 
developed minimal clinical disease with significantly low overall disease burden 
(AUC=22.1±16.4, p=0.031 student’s t-test), very low MMS (1.3±0.9, p<0.0001) and 
significantly delayed disease onset (dDO=12.4±2.9, p=0.0011; Fig. 1B-D). In the same 
direction, no mice died acutely in cPLP group (p=0.052, Kaplan-Meier survival analysis) and 
only 1/10 barely reached score 3 (10% or 1/10 of the cyclic group, p=0.0001, Kaplan-Meier 
survival analysis; Fig. 1E) with the remaining 9/10 having a score between 0 and 2. Overall our 
data indicate that the cyclization of a linear PLP (in the form of the cPLP peptide) significantly 
reduces the clinical encephalitogenic properties of the peptide in the recipient animals. 
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Fig. 1. Clinical course and outcome parameters of animals immunized with linPLP or cPLP. Panel (A) 
shows the long-term (chronic) clinical course and parameters of the animals; on day 16 (white arrow) 
animals were sacrificed for the acute phase, on day 30 (black arrow) animals were sacrificed for the 
chronic phase. The overall burden of disease (mAUC), the maximal disease deficits (MMS, C) and the 
day of disease onset (D) were significantly better in the cPLP animals. Kaplan-Meier survival analysis 
for the % of animals reaching severe clinical scores (≥3) showed that animals immunized with cPLP had 
a mild EAE. Data are displayed as individual values plus mean±SEM. * p<0.05, ** p<0.01, *** p<0.001. 
 
 
2.2. Cyclic PLP causes a minimal pathology in the spinal cords of the animals compared to its 
linear analog  
 
 In order to study the inflammatory, axonopathic and demyelinating processes in the 
mice we analyzed the pathology of spinal cords in both acute and sub chronic phases of the 
disease. During acute phase, the control group had a significant higher inflammatory burden 
within the spinal cords of the mice. The inflammatory load was at least 300% more in the 
control group than cPLP group (linPLP=1371.5±517.4/mm2 and cPLP=439.6±341.7/mm2, 
p<0.001; Fig. 2A). Inflammatory foci were also significantly larger with at least 150% more 
cells in the control group than cyclic group (linPLP=76.7±20.4 and cPLP=31.6±18.5 
cells/focus, p<0.001; Fig. 2B). As an indication of less encephalitogenic potential for the 
 6 
infiltrated cells in the cPLP animals, we also noted a discrepancy between the inflammatory 
load (InfLoad) and the score of some mice in the cPLP group (>350cell/mm2 with clinical score 
of 1), while linPLP mice with a similar InfLoad (>350cells/mm2) had a clinical score ≥3. In 
addition to more inflammation in acute phase, the linPLP group had significant more axonal 
injury than cPLP group (Fisher’s Exact chi-square p<0.001; Fig. 2D,H,I) and more 
demyelination (linPLP=2.7±0.8% and cPLP=0.7±0.4% of spinal cord white matter, p<0.05; Fig. 
2C,F,G). Spheroid and ovoids of axons, which indicate the presence of axonotmesis, were 
only present in the linPLP group and completely absent from the cPLP one (only some 
scattered dystrophic axons). Similarly, axonal density was significant reduced in linPLP 
compared to cPLP group (Fisher’s Exact chi-square p<0.001, Fig. 2E,H,I). Additional and most 
important are the observations that the axonal and myelin integrity and density in cyclic group 
were well preserved even in areas of spinal cord with presence of many inflammatory cells 
(Fig. 2I), whilst control group had injured and lost axons in almost every area adjacent to 
inflammatory foci (Fig. 2H). 
 Sub chronic phase of the disease had no differences between the surviving mice of the 
2 groups concerning the inflammatory load within their spinal cords (linPLP=74.3±49.1/mm2 
and cPLP=82.4±35.4/mm2, p=0.398) and the size of the inflammatory foci (linPLP=18.4±10.0 
and cPLP=13.3±6.0 cells/focus, p=0.254). Axonal pathology (injury and axonal loss) and % 
demyelination (0.2±0.04% and 0.1±0.02% for linPLP and cPLP respectively) were also similar 
between the surviving mice of the 2 groups (p>0.05, supplementary table). However, these 
results must be dealt with critical cautiousness since they represent pathology of mice in the 
control group that survived the acute phase of their disease and had milder clinical scores 
(selection bias due to severe EAE and consequent mortality in the linPLP group). 
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Fig. 2. LinPLP induced very mild encephalitogenic processes in the spinal cords of the immunized 
animals. Inflammatory load (Inf. Load per mm2, A) and size of inflammatory foci (Inf. Size, B) were 
significantly lower in acute phase of cPLP animals; on sub chronic phase inflammatory processes did 
not differ due to selection bias (see text). Demyelination (C) and axonopathic processes (% distribution 
of axonal injury, D, and axonal loss, E) were also significantly milder in cPLP animals compared to 
linPLP during the acute phase, suggesting lower degenerating capacities from the infiltrating cells. 
Pictures F and G show representative longitudinal spinal cord sections (20x) of linPLP and cPLP 
immunized animals stained with LFB (blue: intact myelin, red: cell nuclei; dotted outline in F marks the 
demyelination). Photos H and I show sections (40x) of linPLP and cPLP animals stained with 
Bielschowsky and Hematoxylin (BLS+Hem, evaluation of axonopathy and inflammation; blue: cells 
bodies, dark brown: axons); insert in H shows magnification of a spheroid/ovoid adjacent to 
inflammatory cells (linPLP group) while insert in G shows an intact thick axon next to inflammatory cells 
(cPLP group). Data are displayed as mean±SEM. * denotes p<0.05, *** p<0.001.  
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2.3. Cyclic PLP is less mitogenic/immunogenic than linear PLP  
 
 The in vitro stimulation assays of lymph node cells (LNCs) from linPLP and cPLP mice 
indicate significantly lower mitogenic/stimulatory effects of the cPLP on the lymphocytes 
(LNCs, Figure 3). More specifically, unstimulated cells indicate a similar baseline null 
proliferation of LNCs; addition of a non-specific pan mitogen (concanavalin A) induces a 
similarly strong proliferation in the LNCs from both linPLP and cPLP mice (p>0.5), indicating a 
similar proliferating capacity and intact cell-proliferating mechanisms in both linPLP and cPLP 
LNCs. Under antigen-specific stimulation of the LNCs with their corresponding specific peptide 
(cPLP or linPLP), those from cPLP mice respond 2.5-fold weaker than the linPLP ones 
(p<0.05), indicating a significantly weaker stimulatory capacity of the cPLP peptide compared 
to its linear analog (Fig. 3A). In the same direction, sera from immunized mice showed no anti-
PLP IgG antibody production in cPLP- compared to linPLP-immunized animals (1:200 
dilution), which was equivalent to background naïve mouse sera reactivity (Fig. 3B). These 
data indicate that cyclization of PLP significantly reduces in vivo antibody production capacity. 
Overall, our data suggest that cyclization of the PLP peptide reduces its stimulatory capacity 
on lymphocytes, which results in less PLP-reactive lymphocytes and less IgG. These data are 
in accordance to the our previous clinical and neuropathological data [16].  
 
 
 
 
Fig. 3. (A) In vitro proliferation assays of lymph node cells from linPLP and cPLP immunized mice. 
Unstimulated cells (cells) do not proliferate and are used as baseline control. Cells stimulated with the 
pan-mitogen concanavalin A (+conA) have a similar proliferation potential. Stimulation of the lymph 
node cells with the cPLP caused a significantly lower proliferation rate compared to linPLP re-
stimulation (* p<0.05). # and ## indicates p<0.05 and p<0.01 versus the proliferation of corresponding 
control cells. (B) IgG levels of serum antibodies at 1:200 sera dilution measured by ELISA following 
immunization of mice with linPLP and cPLP. Naïve mouse sera was used as a negative background 
control.  
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2.4. Binding mode of linPLP139-151 and cPLP139-151 peptides in complex with murine MHC class 
II (H2-IAs)  
 
 Previous work has shown that residues L145 and P148 of linPLP139-151 are important for 
the peptide to bind within the H2-IAs binding groove, whereas L141, W144 and H147 are important 
TCR contact amino acids (Fig. 4A) [23]. Given that the main side chain contact points of 
peptides interacting with MHC-II alleles occupy positions P1, P4, P6 and P8, linPLP139-151 was 
modeled as such, with S140, L141, G142, K143, W144, L145, G146, H147 and P148 in allele positions 
P1-9 respectively. In addition, the electrostatic potential continuum of H2-IAs was calculated 
(Fig. 4B) supporting the modelled binding position of the linear peptide, in which P6 appears to 
be hydrophobic, therefore should accommodate L145 and P4 is highly negatively charged 
suggesting that it is a binding region for the positively charged side chain of K143 (Fig. 4B).   
 As shown in Figure 4C for linPLP139-151, the specific electrostatic binding elements to 
the cavity are hydrogen bonds made by the S140 hydroxyl group with T52α in P1 and H147 with 
T56α and strong polar contacts include K143 interacting with E74β and D30β in P4 as 
mentioned previously, as well as D149 forming a polar bridge with R76α. The basic hydrophobic 
contacts represented are L145 buried deep in P6 interacting with F11β, F13β and Y32β in a 
highly hydrophobic region of H2-IAs and the P148 non-polar interactions with Y63β and I72α as 
it is located between them. Based on this topology of the linear peptide, it is clear that the main 
potential TCR contact residues are L141, W144 and H147, as has been previously reported [23].  
 In the case of cPLP139-151, critical interactions for binding within the cavity of the MHC 
allele are maintained, such as K143 in P4, L145 in P6 and P148 in P9. These residues maintain 
their interactions with E74β and D30β (K143), F11β, F13β and Y32β (L145) and Y63β and I72α 
(P148) (Fig. 4D). However, cyclization does not allow S140 to interact with T52α or H147 with 
T56α, neither D149 forms a polar interaction with R76α due to conformational restrictions of the 
cyclization. What is interesting is that the TCR interaction interface in largely changed, with 
positions P5 and P8 occupied by H147 and F151 and K150 respectively. Even though L141 
maintains its relative position towards the TCR, W144 is somewhat replaced by H147 and the 
most significant change is F151 and K150 pointing up, thus replacing the role of H147 of the linear 
counterpart in P8 (Figs. 4C, 4D). Hence, the conformational differences underlying the binding 
elements noted for cPLP vs. linPLP in complex with H2-IAs may account for the significant 
different pathological outcomes of the peptides. 
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Fig. 4. Computational structural models of linear and cyclic PLP139-151. (A) H2-IAs and TCR contact 
points for linPLP based on the results by Kuchroo et al. [23]. (B) Continuum of electrostatics of the 
surface for H2-IAs, performed using APBS (±12 kT/e).  Red color is for negative and blue for positive, 
whereas linPLP is depicted in yellow. (C) Mode of linPLP (in yellow) binding to H2-IAs and (D) mode of 
cPLP (in orange) binding to H2-IAs. H2-IAs chains α and β are depicted in green and blue color 
respectively. Peptide labels appear in red, H2-IAs in black and van der Waals surface is shown in white 
color.  
 
 
3. Conclusion 
 The present experimental study indicates a reduced encephalitogenic effect of cPLP 
peptide compared to its linear analog. Our preclinical and histopathological data of acute 
phase (highest disease activity) converge to the fact that cPLP is less potent in causing tissue 
damage and a consequent of clinical disease. Of special interest is that mice from both groups 
with similar inflammatory burden in their spinal cords displayed different clinical severity scores 
depending on whether they were immunized with the linear or the cyclic peptide (very low 
scores in the cPLP animals and severe score in the linPLP ones). This is in agreement to the 
in vitro restimulation data of LNCs, which confirmed the lower stimulatory effects of cPLP 
compared to the linPLP peptide, and to the reduced in vivo anti-IgG PLP antibody production 
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in cPLP-immunized animals compared to linPLP. These data collectively indicate that the 
cyclization of a linear encephalitogenic peptide reduces the activation of lymphocytes and their 
specificity to their antigenic targets in the CNS tissue.  
 The minimal clinical, immunogenic and tissue pathology induced by the cyclic peptide 
could be theoretically explained by its intracellular processing and breaking into linear peptides 
following its uptake from the antigen-presenting cells. Previous studies from our group with 
other cyclic peptides indicate that despite higher stability of a cyclic peptide to lysosomal 
enzymes versus its linear analog, it can still produce degradation by-products that can have a 
residual activatory potential on lymphocytes [27-30]. This mechanism could be responsible for 
the observed mild clinical disease and pathology but it is not capable to induce the complete 
spectrum and severity of the linear peptide. The similar residual inflammatory, demyelinating 
and axonopathic processes of subchronic phase should be cautiously viewed under the 
spectrum of high selection bias in the linPLP group (due to mortality) that has removed from 
the longer follow-up the more severely affected mice. Evidently, the degradation by-products 
could also probably explain a relatively high cPLP potential (equal to linPLP) to induce in vitro 
IFN-gamma secreting T-lymphocytes, as we showed previously [16], although these cells 
seem less primed to target the correct (i.e. linear) peptide in vivo and cause the maximum of 
tissue damage. 
 The modeling studies suggest that linear and cyclic PLP139-141 peptides share similar 
conformational profiles when it comes to MHC binding but more importantly, very different 
profiles in regards to potential TCR recognition and interaction sites, which is supported by 
other studies [23]. More specifically, for linPLP, primary TCR contacts are L141, W144 and H147 
at positions P2, P5 and P8 respectively (Fig. 4C), in contrast to cPLP, where L141 is maintained 
in P2, but H147 is localized in P5 and F151 and K150 occupy P8. This differentiation in the 
topology of peptide TCR contacts gives insights into the likely mechanisms regarding the 
different pathological and immunological outcomes noted in SJL/J mice. 
 Most importantly, the present data with the cPLP peptide in SJL/J mice are in complete 
agreement to our previous findings with a cMOG peptide in another mouse strain (C57BL/6 
mice) [26], suggesting that the concept of a peptide-cyclization is valid in different strains and 
conditions. As the cyclization concept could be applied in other strains and peptides as well, 
we provide for the first time the proof-of-concept for a novel future therapeutic regime of 
multiple autoimmune disorders (not only CNS-related but with other organ-targets) on a 
peptide-, disease- and patient-selective basis. 
 
 
4. Experimental section 
 
4.1. Solid phase peptide synthesis of linear and cyclic PLP139-151 
 
 The synthesis of linear PLP139-151 (linPLP) and cyclo(139-151) PLP139-151 (cPLP) 
peptides, H139SLGKWLGHPDKF151 (rat, mouse) were synthesized at ELDrug SA (Patras 
Science Park, Greece) (Fig. 5) [31, 32]. Following assessment using analytical HPLC and 
mass spectroscopy (ESI-MS) peptides were shown to be > 98 % pure as we previously 
published [16]. 
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Fig. 5. Synthetic procedure for linear and cyclic PLP peptides 
 
 
4.2. Animal handling  
 
 Female SJL/J mice, 8 weeks-old, were purchased from Hellenic Pasteur Institute, 
Athens, and housed in the P3 animal facility of the B’ Neurological Department of the AHEPA 
University Hospital, Aristotle University Medical School, Greece.  Animals were handled in 
accordance with the National Institute of Health guidelines, were fed a regular diet and given 
water without antibiotics.  
 
4.3. Experimental groups and induction of EAE. 
 
 Animals were randomly divided into 2 experimental groups: 1) the control group which 
received the linear PLP139-151 (linPLP, n=9), and 2) the cyclic-PLP139-151 group (cPLP, n=10) 
which received the corresponding cyclic PLP139-151 peptide. EAE was induced in SJL/J mice 
using a common vaccination scheme but each animal received the corresponding peptide 
(linPLP or cPLP) according to its group. Briefly, on day 0 (day of disease induction) each 
mouse received subcutaneously (sc) 150 μg of the respective PLP139-151 peptide (linear or 
cyclic) in its hindlimb plantar. The peptides were diluted in 50 μl of PBS and were emulsified 
with 50 μl of CFA (8 mg/ml Mycobacterium Tuberculosis HR37a in Incomplete Freund’s 
Adjuvant) per animal, thus producing an emulsion of 100 μl final volume per animal. On the 
same day (day 0), each mouse received additionally 400 ng pertussis toxin intraperitoneally 
(ip), dissolved in 500 μl filtered PBS. On day 2 animals received an ip booster of pertussis 
toxin (200 ng pertussis toxin dissolved in 500 μl filtered PBS per animal). 
 13 
 Animals were daily evaluated for clinical signs of disease, starting from day 1 post 
immunisation, using a 6-grade clinical scale, as previously described [26, 33]: 0= normal 
animal, 1= inability to elevate the tail above the horizontal level, 2= flail tail, 3= score 2 plus 
inability to turn from supine to prone position, 4= score 3 plus paresis or paralysis of hind 
limbs, 5= score 4 plus paresis of front limbs, 6= death from EAE. Moreover, animals were daily 
weighted throughout the entire experimental period to evaluate body weight loss due to the 
induced disease.  
 
4.4. Histopathology 
 
 Animals were humanly sacrificed under deep anaesthesia at acute phase of the 
disease (day 16) and at a sub chronic phase (day 31) of their disease. Their clinical scores at 
the days of sacrifices were recorded and used for correlations. All animals were transcardially 
perfused with ice cold PBS (approximately 30 seconds) followed by ice cold 4% 
paraformaldehyde in PBS (4% PFA) for 5 minutes. Brains and spinal cords were removed, 
post-fixed overnight in 4% PFA, cryoprotected by incubation for 3-4 days in 30% sucrose and 
then routinely processed for sagittal or longitudinal cryostat sectioning at 6 μm. Due to 
prevalence of inflammatory, axonopathic and demyelinating processes in the spinal cords of 
the animals, all relative histopathological studies were focus in spinal cords.  
 Axonal and inflammatory pathology were studied on longitudinal spinal cord sections 
stained with a modified Bielschowsky silver impregnation method combined with Haematoxylin 
counterstaining, as we previously established [26, 33, 34]. Evaluation of axonopathy and 
inflammatory burden was performed under a light microscope (Olympus Axioplan-2) by 2 
group-blinded evaluators on 3 different longitudinal spinal cord sections spaced approximately 
100 μm apart. Using previously established semi-quantitative scales [26, 33], axonal pathology 
was evaluated under high power (40x) observation. Axonal injury (AI) was evaluated using a 
0-4 semi quantitative scale [26] (0 = no AI, 1+ = scattered dystrophic injured axons without any 
spheroid or ovoid, 2+ = mild AI with the presence of at least one spheroid or ovoid, 3+ = 
moderate AI, 4 + = severe AI). Injured axons were either identified as spheroids and ovoids 
(which represent axonotmesis) or dilated (dystrophic) axons which represent injured axons not 
yet being cut. Axonal loss (AL) was evaluated using the following scale [0 = normal axonal 
density, 1+ = increased interaxonal distances (<25% AL), 2+ = mild AL (26–50%), 3+ = 
moderate to severe (51–75%) AL, 4+ = severe AL (>75%)]. It is important to note that score of 
AL “1+” did not represent a true reduction of axons but rather increased interaxonal distances 
due to tissue oedema, a phenomenon that was reversible after oedema reduction at sub 
chronic phase. Inflammatory processes were evaluated by the size of inflammatory foci 
(number of inflammatory cells per perivascular inflammatory foci, “InfSize”) and the total 
inflammatory load of the tissue number of inflammatory cells -perivascular and parenchymal- 
(“InfLoad”), under 20x optical fields with the aid of a prefrontal grid. 
 Demyelinating procedures were evaluated on longitudinal sections stained with Luxol 
fast Blue and counterstained with Nuclear Fast Red using standard protocols [26, 33]. 
Evaluation was performed on 3 spinal cord sections as described above for axonopathy, under 
20x optical fields with the aid of a prefrontal microscope grid: we measured the total (intact and 
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lesioned) and the demyelinating (lesioned) surface of the spinal cord's white matter for each 
optical field and then calculated the % percentage of white matter's demyelination (% Dem). 
 
4.5. Immunological assays 
 
4.5.1. Cell proliferation assay 
 
 At day 10 post- induction animals of either linPLP or cPLP groups were euthanized 
with diethyl-ether and their inguinal lymph nodes were extracted. After dissociation of the 
lymph nodes of each animal on a petri-dish containing a sterile mesh, the cells were collected 
and washed from tissue debris with two sequential centrifugations (1500 rpm, 10 min) in full 
growth medium [0.3% 2-mercaptethanol solution (0.1%) (Sigma), 1% 100 mM sodium 
pyruvate (Gibco), 1% 200 mM glutamine 1 x (Gibco), 5% fetal calf serum (Gibco), 1% 
penicillin/streptomycin (Gibco), 1% MEM non-essential amino acids 100 x (Gibco) and 90.7% 
RPMI 1640 with glutamine (Gibco)]. The isolated LNCs were then transferred into 96- well 
plates at a concentration of 4 x 105 cells per well and incubated in triplicates, in presence of 
their specific antigens (cyclic or linear PLP peptide, 100 μg/ml/well, specific activation) or 
unspecific mitogens (1 μg/ml/well ConA, unspecific activation), for 48 hours at 37°C and 5% 
CO2. Plain LNCs from linPLP or cPLP groups (without any addition) were used as controls 
(baseline mean proliferation rhythm of the cells).  
 Following the incubation of 48 hours, viability and proliferation of lymphocytes were 
evaluated using the 3-4,5-dimethylthiazol-2-yl-2,5-diphenyltetrazolium bromide (MTT) 
proliferation assay, according to manufacturer instruction (R&D Systems). Results of optical 
absorbance (OD) of each well were obtained using a spectrophotometer at 540nm and were 
used for calculation of % cell proliferation [= mean OD of the corresponding wells / OD of 
unstimulated LNCs) *100].  
 
4.5.2. Antibody ELISA assay 
 
Blood was collected and sera was isolated from mice prior to and 4 weeks after 
immunization with CFA. linPLP139-151 and cPLP139-151 peptides were conjugated to BSA and 
coated onto polyvinyl chloride (PVC) microtiter plates at 10 μg/ml in 0.2 M NaHCO3 buffer, pH 
9.6, O/N at 4° C. Non-specific binding was blocked with 2% BSA for 1 hour at room 
temperature. Following washing of plates with 0.05% Tween 20/PBS, 1/200 dilutions of sera 
were added and incubated for a further 2 hours at room temperature after which bound 
antibody was detected using HRP-conjugated sheep anti-mouse antibody (1/1000 dilution in 
PBS) (Amersham, UK) and developed using 2,2’-azino-di(3-ethylbenzthiazoline)6-sulfonic acid 
(ABTS) (Sigma, UK). Absorbance at 405nm was read using a Fluostar Optima microplate 
reader (BMG labtech, Offenburg, Germany). 
 
4.6. Statistical analysis 
 
 Statistical analysis of the data was performed using the SPSS 23.0 and GraphPad 
Prism 6 software. Scale clinical, histopathological and in vitro proliferation data were initially 
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tested for normality using Shapiro-Wilk test to assess their validity for parametric analysis 
(Student’s t-test). For non-parametric analysis of two groups we used the Mann-Whitney U 
test. For comparison of nominal or ordinal data we applied a Pearson chi-square test or 
Fisher’s exact test, depending on the tables’ properties. Animals that died due to EAE (score 
6) were mathematically kept within their group until end of follow-up to avoid masking of the 
true clinical group condition and thus confer data bias. The total disease burden (evaluated as 
the area under the curve, AUC), the maximal disease severity (evaluated as the mean 
maximal score, MMS) and the day of disease onset (mean day of disease onset with a clinical 
score of 1, dDO) for each group were calculated as previous described in detail [26, 35]. 
Survival analysis was performed using Mantel-Cox log-rank test (Kaplan-Meier survival 
analysis). Values are expressed as mean±SE. For antibody assays, mean values were 
compared using the Student’s two-tailed t-test. P value threshold indicates a statistically 
significant difference where, of * p<0.05, ** p<0.01, *** p<0.001 
 
4.7. Computational models of linear and cyclic PLP139-151 peptides in complex with murine H2-
IAs 
 
The H2-IAu complex, comprising of the MBP1–11 peptide crystal structure (PDB ID: 1k2d; 2.20 Å 
resolution) [36] was used as a template for the H2-IAs complex homology model as in previous 
studies [37]. The primary sequence of the two chains were obtained from the Universal Protein 
Resource (UNIPROT) database (UNIPROT IDs: P14437.1 and P06345.1 respectively). The 
homology model was built using MODELLER v9.7 [38] and the construction involved the 
disulfide bonds between C107 - C163 in chain α and C15 – C79 and C117 – C173 in chain β. 
The overall stereochemical quality of the final model was evaluated by the discrete optimized 
energy (DOPE) and thorough visual inspection. The linear peptides were docked in the cleft by 
means of structural alignment according to previous studies [23]. The cyclic peptide (cPLP) was 
constructed via manual N- and C-terminal bonding of the linear peptide following energy 
minimization using the conjugate gradient algorithm.  Electrostatic surface calculations on H2-IAs 
were performed using PDB2PQR [39] to prepare the protein and Pymol APBS default settings 
[40]. 
 
Acknowledgements 
 
 M-TM was supported in part by an IKY fellowship of excellence for postgraduate 
studies in Greece - Siemens program. VA would like to thank Vianex SA Greece for support 
(Specific task agreement MS immunotherapeutics). VA and JM would like to thank Vianex SA 
Greece for their enthusiasm, support and helpful discussions regarding drug development and 
immunotherapeutics against MS. In addition, we thank ELDrug SA and its personnel for 
synthetic and analytical work. 
 
Author contributions 
 
 AL designed and performed EAE experiments, acquired and/or analyzed 
clinical/histology/T-cell data and wrote the manuscript. AG and RL were involved in EAE and 
 16 
T-cell experiments; MK and VA acquired and analyzed the antibody data. M-TM performed the 
computational studies and GD synthesized the peptides. NG, JM and VA discussed the 
project, provided intellectual input, planned experiments, wrote and edited the manuscript and 
supervised all staff. 
 
References 
 
[1] N. Grigoriadis, T. Ben-Hur, D. Karussis, I. Milonas, Axonal damage in multiple 
 sclerosis: a complex issue in a complex disease, Clin Neurol Neurosurg, 106 (2004) 
 211-217. 
[2]  A. Ben-Nun, I.R. Cohen, Experimental autoimmune encephalomyelitis (EAE) mediated 
 by T cell lines: process of selection of lines and characterization of the cells, J 
 Immunol, 129 (1982) 303-308. 
[3]  V.K. Kuchroo, R.A. Sobel, T. Yamamura, E. Greenfield, M.E. Dorf, M.B. Lees, 
 Induction of experimental allergic encephalomyelitis by myelin proteolipid-protein-
 specific T cell clones and synthetic peptides, Pathobiology, 59 (1991) 305-312. 
[4]  S. Zamvil, P. Nelson, J. Trotter, D. Mitchell, R. Knobler, R. Fritz, L. Steinman, T-cell 
 clones specific for myelin basic protein induce chronic relapsing paralysis and 
 demyelination, Nature, 317 (1985) 355-358. 
[5]  J.M. Greer, V.K. Kuchroo, R.A. Sobel, M.B. Lees, Identification and characterization of 
 a second encephalitogenic determinant of myelin proteolipid protein (residues 178-191) 
 for SJL mice, J Immunol, 149 (1992) 783-788. 
[6]  J.M. Greer, R.A. Sobel, A. Sette, S. Southwood, M.B. Lees, V.K. Kuchroo, 
 Immunogenic and encephalitogenic epitope clusters of myelin proteolipid protein, J 
 Immunol, 156 (1996) 371-379. 
[7]  V.K. Tuohy, Z. Lu, R.A. Sobel, R.A. Laursen, M.B. Lees, Identification of an 
 encephalitogenic determinant of myelin proteolipid protein for SJL mice, J Immunol, 
 142 (1989) 1523-1527. 
[8]  M. Degano, K.C. Garcia, V. Apostolopoulos, M.G. Rudolph, L. Teyton, I.A. Wilson, A 
 functional hot spot for antigen recognition in a superagonist TCR/MHC complex, 
 Immunity, 12 (2000) 251-261. 
[9]  M. Kalbus, B.T. Fleckenstein, M. Offenhausser, M. Bluggel, A. Melms, H.E. Meyer, 
 H.G. Rammensee, R. Martin, G. Jung, N. Sommer, Ligand motif of the autoimmune 
 disease-associated mouse MHC class II molecule H2-A(s), Eur J Immunol, 31 (2001) 
 551-562. 
[10]  L. Kappos, G. Comi, H. Panitch, J. Oger, J. Antel, P. Conlon, L. Steinman, Induction of 
 a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis 
 after administration of an altered peptide ligand in a placebo-controlled, randomized 
 phase II trial. The Altered Peptide Ligand in Relapsing MS Study Group, Nat Med, 6 
 (2000) 1176-1182. 
[11] S.W. Brostoff, D.W. Mason, Experimental allergic encephalomyelitis: successful 
 treatment in vivo with a monoclonal antibody that recognizes T helper cells, J Immunol, 
 133 (1984) 1938-1942. 
[12]  L. Steinman, J.T. Rosenbaum, S. Sriram, H.O. McDevitt, In vivo effects of antibodies to 
 immune response gene products: prevention of experimental allergic encephalitis, 
 Proceedings of the National Academy of Sciences of the United States of America, 78 
 (1981) 7111-7114. 
[13]  M.K. Waldor, S. Sriram, R. Hardy, L.A. Herzenberg, L.A. Herzenberg, L. Lanier, M. 
 Lim, L. Steinman, Reversal of experimental allergic encephalomyelitis with monoclonal 
 antibody to a T-cell subset marker, Science, 227 (1985) 415-417. 
 17 
[14]  M. Katsara, G. Deraos, T. Tselios, J. Matsoukas, V. Apostolopoulos, Design of novel 
 cyclic altered peptide ligands of myelin basic protein MBP83-99 that modulate immune 
 responses in SJL/J mice, Journal of medicinal chemistry, 51 (2008) 3971-3978. 
[15]  M. Katsara, G. Deraos, T. Tselios, M.T. Matsoukas, I. Friligou, J. Matsoukas, V. 
 Apostolopoulos, Design and synthesis of a cyclic double mutant peptide (cyclo(87-
 99)[A91,A96]MBP87-99) induces altered responses in mice after conjugation to 
 mannan: implications in the immunotherapy of multiple sclerosis, Journal of medicinal 
 chemistry, 52 (2009) 214-218. 
[16]  M. Katsara, S. Deraos, T.V. Tselios, G. Pietersz, J. Matsoukas, V. Apostolopoulos, 
 Immune responses of linear and cyclic PLP139-151 mutant peptides in SJL/J mice: 
 peptides in their free state versus mannan conjugation, Immunotherapy, 6 (2014) 709-
 724. 
[17]  M. Katsara, J. Matsoukas, G. Deraos, V. Apostolopoulos, Towards immunotherapeutic 
 drugs and vaccines against multiple sclerosis, Acta Biochim Biophys Sin (Shanghai), 
 40 (2008) 636-642. 
[18]  M. Katsara, G. Minigo, M. Plebanski, V. Apostolopoulos, The good, the bad and the 
 ugly: how altered peptide ligands modulate immunity, Expert Opin Biol Ther, 8 (2008) 
 1873-1884. 
[19]  M. Katsara, E. Yuriev, P.A. Ramsland, G. Deraos, T. Tselios, J. Matsoukas, V. 
 Apostolopoulos, A double mutation of MBP(83-99) peptide induces IL-4 responses and 
 antagonizes IFN-gamma responses, Journal of neuroimmunology, 200 (2008) 77-89. 
[20]  M. Katsara, E. Yuriev, P.A. Ramsland, G. Deraos, T. Tselios, J. Matsoukas, V. 
 Apostolopoulos, Mannosylation of mutated MBP83-99 peptides diverts immune 
 responses from Th1 to Th2, Mol Immunol, 45 (2008) 3661-3670. 
[21]  M. Katsara, E. Yuriev, P.A. Ramsland, T. Tselios, G. Deraos, A. Lourbopoulos, N. 
 Grigoriadis, J. Matsoukas, V. Apostolopoulos, Altered peptide ligands of myelin basic 
 protein ( MBP87-99 ) conjugated to reduced mannan modulate immune responses in 
 mice, Immunology, 128 (2009) 521-533. 
[22]  M.K. Keramida, T. Tselios, E. Mantzourani, K. Papazisis, T. Mavromoustakos, C. 
 Klaussen, G. Agelis, S. Deraos, I. Friligou, H. Habibi, J. Matsoukas, Design, synthesis, 
 and molecular modeling of a novel amide-linked cyclic GnRH analogue cyclo(4-
 9)[Lys4,D-Trp6,Glu9]GnRH: stimulation of gonadotropin gene expression, Journal of 
 medicinal chemistry, 49 (2006) 105-110. 
[23]  V.K. Kuchroo, J.M. Greer, D. Kaul, G. Ishioka, A. Franco, A. Sette, R.A. Sobel, M.B. 
 Lees, A single TCR antagonist peptide inhibits experimental allergic encephalomyelitis 
 mediated by a diverse T cell repertoire, J Immunol, 153 (1994) 3326-3336. 
[24]  V.K. Kuchroo, R.A. Sobel, J.C. Laning, C.A. Martin, E. Greenfield, M.E. Dorf, M.B. 
 Lees, Experimental allergic encephalomyelitis mediated by cloned T cells specific for a 
 synthetic peptide of myelin proteolipid protein. Fine specificity and T cell receptor V 
 beta usage, J Immunol, 148 (1992) 3776-3782. 
[25]  M.P. Yannakakis, C. Simal, H. Tzoupis, M. Rodi, N. Dargahi, M. Prakash, A. Mouzaki, 
 J.A. Platts, V. Apostolopoulos, T.V. Tselios, Design and Synthesis of Non-Peptide 
 Mimetics Mapping the Immunodominant Myelin Basic Protein (MBP83-96) Epitope to 
 Function as T-Cell Receptor Antagonists, International journal of molecular sciences, 
 18 (2017). 
[26]  A. Lourbopoulos, G. Deraos, M.T. Matsoukas, O. Touloumi, A. Giannakopoulou, H. 
 Kalbacher, N. Grigoriadis, V. Apostolopoulos, J. Matsoukas, Cyclic MOG35-55 
 ameliorates clinical and neuropathological features of experimental autoimmune 
 encephalomyelitis, Bioorganic & medicinal chemistry, 25 (2017) 4163-4174. 
 18 
[27]  M. Katsara, T. Tselios, S. Deraos, G. Deraos, M.T. Matsoukas, E. Lazoura, J. 
 Matsoukas, V. Apostolopoulos, Round and round we go: cyclic peptides in disease, 
 Current medicinal chemistry, 13 (2006) 2221-2232. 
[28]  G. Deraos, M. Rodi, H. Kalbacher, K. Chatzantoni, F. Karagiannis, L. Synodinos, P. 
 Plotas, A. Papalois, N. Dimisianos, P. Papathanasopoulos, D. Gatos, T. Tselios, V. 
 Apostolopoulos, A. Mouzaki, J. Matsoukas, Properties of myelin altered peptide ligand 
 cyclo(87-99)(Ala91,Ala96)MBP87-99 render it a promising drug lead for 
 immunotherapy of multiple sclerosis, European journal of medicinal chemistry, 101 
 (2015) 13-23. 
[29]  J. Matsoukas, V. Apostolopoulos, H. Kalbacher, A.M. Papini, T. Tselios, K. 
 Chatzantoni, T. Biagioli, F. Lolli, S. Deraos, P. Papathanassopoulos, A. Troganis, E. 
 Mantzourani, T. Mavromoustakos, A. Mouzaki, Design and synthesis of a novel potent 
 myelin basic protein epitope 87-99 cyclic analogue: enhanced stability and biological 
 properties of mimics render them a potentially new class of immunomodulators, 
 Journal of medicinal chemistry, 48 (2005) 1470-1480. 
[30]  T. Tselios, V. Apostolopoulos, I. Daliani, S. Deraos, S. Grdadolnik, T. 
 Mavromoustakos, M. Melachrinou, S. Thymianou, L. Probert, A. Mouzaki, J. 
 Matsoukas, Antagonistic effects of human cyclic MBP(87-99) altered peptide ligands in 
 experimental allergic encephalomyelitis and human T-cell proliferation, Journal of 
 medicinal chemistry, 45 (2002) 275-283. 
[31]  K. Barlos, D. Gatos, 9-Fluorenylmethyloxycarbonyl/ tbutyl-based convergent protein 
 synthesis, Biopolymers, 51 (1999) 266-278. 
[32]  K. Barlos, D. Gatos, S. Koutsogianni, Fmoc/Trt-amino acids: comparison to Fmoc/tBu-
 amino acids in peptide synthesis, J Pept Res, 51 (1998) 194-200. 
[33]  A. Lourbopoulos, N. Grigoriadis, R. Lagoudaki, O. Touloumi, E. Polyzoidou, I. 
 Mavromatis, N. Tascos, A. Breuer, H. Ovadia, D. Karussis, E. Shohami, R. 
 Mechoulam, C. Simeonidou, Administration of 2-arachidonoylglycerol ameliorates both 
 acute and chronic experimental autoimmune encephalomyelitis, Brain research, 1390 
 (2011) 126-141. 
[34]  A. Lourbopoulos, N. Grigoriadis, C. Symeonidou, G. Deretzi, N. Taskos, E. Shohami, 
 Modified Bielschowsky silver impregnation combined with Hematoxylin or Cresyl Violet 
 counterstaining as a potential tool for the simultaneous study of inflammation and 
 axonal injury in the central nervous system, Aristotle University Med J 34 (2007) 31-39. 
[35]  K.K. Fleming, J.A. Bovaird, M.C. Mosier, M.R. Emerson, S.M. LeVine, J.G. Marquis, 
 Statistical analysis of data from studies on experimental autoimmune 
 encephalomyelitis, Journal of neuroimmunology, 170 (2005) 71-84. 
[36]  X.L. He, C. Radu, J. Sidney, A. Sette, E.S. Ward, K.C. Garcia, Structural snapshot of 
 aberrant antigen presentation linked to autoimmunity: the immunodominant epitope of 
 MBP complexed with I-Au, Immunity, 17 (2002) 83-94. 
[37]  V. Apostolopoulos, G. Deraos, M.T. Matsoukas, S. Day, L. Stojanovska, T. Tselios, 
 M.E. Androutsou, J. Matsoukas, Cyclic citrullinated MBP87-99 peptide stimulates T cell 
 responses: Implications in triggering disease, Bioorganic & medicinal chemistry, 25 
 (2017) 528-538. 
[38]  B. Webb, A. Sali, Comparative protein structure modeling using Modeller, Current 
 protocols in bioinformatics, (2014) 5.6. 1-5.6. 32. 
[39]  T.J. Dolinsky, P. Czodrowski, H. Li, J.E. Nielsen, J.H. Jensen, G. Klebe, N.A. Baker, 
 PDB2PQR: expanding and upgrading automated preparation of biomolecular 
 structures for molecular simulations, Nucleic acids research, 35 (2007) W522-525. 
[40]  N.A. Baker, D. Sept, S. Joseph, M.J. Holst, J.A. McCammon, Electrostatics of 
 nanosystems: application to microtubules and the ribosome, Proceedings of the 
 19 
 National Academy of Sciences of the United States of America, 98 (2001) 10037-
 10041. 
 
 
